key: cord-0740286-siy06uxm
authors: Zacharias, Hannah; Dubey, Shirish; Koduri, Gouri; D'Cruz, David
title: Rheumatological complications of Covid 19
date: 2021-07-05
journal: Autoimmun Rev
DOI: 10.1016/j.autrev.2021.102883
sha: 823afb42d24ac8e80a5ca9553b6af97b557e20ec
doc_id: 740286
cord_uid: siy06uxm

INTRODUCTION: COVID-19 has caused unprecedented hardships in the 21st century with more than 150 million infections. Various immunological phenomena have been described during the course of the infection, and this infection has also triggered autoimmunity. Rheumatological illnesses have been described following resolution of the acute infection; hence we sought to conduct a review of the rheumatological complications of COVID-19. METHODS: We conducted a literature search for articles relating to sequelae of COVID-19 from Jan 2020 to 30th April 2021. RESULTS: We found a number of reports of inflammatory arthritis after SARS-CoV-2 infection. SLE and renal disease have been described, and vasculitis also appears to be a common complication. Rhabdomyolysis and myositis has also been reported in a number of patients. We also found some evidence of large vessel vasculitis in ‘long COVID’ patients. CONCLUSIONS: This review highlights a number of important complications such as inflammatory arthritis, lupus-like disease, myostis and vasculitis following SARS-CoV-2 infection.

The effects of SARS-CoV-2 on the immune system and cytokine profiles are still unclear.

Several reports have been published describing the immunological alterations seen with COVID-19. These range from a maladaptive immune response and abnormal cytokine production, to hyperactivation of T cells and increased numbers of activated monocytes, macrophages and neutrophils, which may ultimately result in untoward consequences [12] [13] [14] . The emergence of several autoimmune/autoinflammatory phenomena has been described such as Guillian-Barré syndrome, immune thrombocytopenia, Miller Fischer syndrome and type 1 diabetes mellitussee table 1 for full details [15] . Rheumatological manifestations these include inflammatory arthritis (viral arthritis, reactive arthritis, chronic arthritis, rheumatoid arthritis), lupus like syndromes, vasculopathy (Kawasaki-like disease, chilblain lesions, vasculitis) and a chronic fatigue spectrum disorder. Table 1 In this narrative review, we describe the rheumatic manifestations during and after the illness as well as the pathophysiologic mechanisms of autoimmune problems which may enable these illnesses following COVID-19 infection.

Our objective was to narrate the rheumatic manifestations that are associated with or follow

The search terms, used both separately and in combination, included: "transmission," "COVID-19," "coronavirus," "SARS-CoV-2," "reactive", "viral", "arthritis, "ANCA", "vasculitis", "long haul", "long COVID" "chronic fatigue" (long COVID), "Lupus", "SLE" "Kawasaki", "Paediatric Inflammatory Multisystem Syndrome temporally related with COVID-19", "PIMS-TS", "Multisystem Inflammatory Syndrome in Children", "MIS-C", "rheumatic", "autoimmune", "musculoskeletal", "myositis", "scleroderma".

We have divided the results into various sections for ease of understanding and based on pathological groupings. These include inflammatory arthritis, connective tissue disorders including SLE/ lupus-like disease and myositis, renal disease and vasculitis.

Viral infections can cause arthritis and the spectrum of symptoms can range from mild arthralgia to spurious and chronic arthritis [16] . Chronic arthritis has been reported in association with hepatitis C and several endemic alphaviruses such as Chikungunya, whereas self-limited arthritis can occur with parvovirus B19, rubella or hepatitis B virus. By contrast, coronaviruses seem to typically cause arthralgia and myalgia rather than a true inflammatory arthritis [1, [17] [18] [19] [20] [21] . Arthralgia is reported in 15% of patients with COVID-19, and myalgia has been reported in 44% of patients [1, 16] . Musculoskeletal symptoms, however, do not seem to be associated with COVID-19 severity [1] . Respiratory viral infections have also been associated with an increased number of cases of rheumatoid arthritis (RA) [20] . Our literature search revealed a few cases of reactive arthritis following SARS-CoV-2 infection alongside five cases of RA and two cases of seronegative spondyloarthropathy. These cases were in different age groups with varied disease courses, as well as presentations in the joints of the upper and lower extremities.

The first case involved a male patient in his 50s who was admitted with COVID-19 pneumonia. On day 21, he developed acute bilateral ankle arthritis with mild enthesitis in his right Achilles tendon, but without any other features of reactive arthritis [22] . The second case was a 73-year-old man who developed acute arthritis of the small joints of the hands and feet after 8 days of completion of COVID-19 treatment [23] . The third case was a 47-year-old man who presented with a three-day history of progressive right knee pain and swelling and pain in his glans penis. Investigations for HIV, syphilis, chlamydia, and gonorrhoea were negative as well as arthrocentesis [24] . A 65-year-old woman with HLA B27 positivity developed symmetrical arthritis of ankles, knees and wrists and a cutaneous vasculitis ten days after cessation of all COVID-19-related symptoms [25] . Another patient developed inflammatory arthralgia with cyclic citrullinated peptide (CCP) antibodies which resolved with a short course of oral corticosteroids [26] . Furthermore, a 39-year-old Saudi Arabian woman, developed synovitis in the PIP and DIP joints, 2 weeks after recovery from COVID-19 infection [27] . Two cases of monoarthritis were also described after resolution of COVID-19. A report described a patient with elbow arthritis associated with psoriatic skin lesions with no previous history of dactylitis or arthritis [28] and another report described a patient with severe right wrist pain and swelling 2 weeks after COVID-19 [29] . A young healthy sixteen-year-old girl developed dactylitis of the left toes after 3 weeks of contracting COVID-19 which resolved with NSAIDs [30] . Yokogawa and colleagues described a man with knee arthritis occurring during COVID-19, resolving spontaneously, suspected to be a viral arthritis [31] . Langhoff Hønge et al describe a case that presented with acute polyarthritis and J o u r n a l P r e -p r o o f fever a few days after discharge from hospital with COVID-19 and responded well to treatment as reactive arthritis [32] .

Baimukhamedov et al describe a case with new onset of RA with polyarticular presentation 3 weeks after diagnosis of COVID-19 initially with only rheumatoid factor positivity but subsequently also CCP positivity as well. This patient was treated with Methotrexate and corticosteroids [33] . Derksen et al report 3 patients who developed seropositive RA on average 6.6 weeks after Covid-19 infection [34] . Another patient was reported by Roongta et al who describe a 56 year old woman who developed seropositive RA with joint symptoms starting 2-3 weeks after recovery from Covid-19 [35] . To date there is only one paediatric case described in the literature; a 10-year-old boy presented with oligoarthritis, fever and urticaria [36] .

The first case of Spondyloarthropathy triggered by SARS-CoV-2 infection was reported in a genetically predisposed (family history of psoriasis, HLA B27 negative) woman [37] .

Another case was reported of a 53 year old man who developed inflammatory back pain with sacroilitis on MRI following asymptomatic COVID-19 infection [38] . A Spanish study noted that in their cohort of 306 patients with proven COVID-19, eighty-one (26.4%) complained of muscle and joint pains at presentation but only four (1.3%) developed acute arthritis during hospitalisation and all were proven crystal arthropathy [39] .

Indeed, the majority of cases are in keeping with reactive arthritis generally developing between 1-3 weeks after the infection. Interestingly, the cases of RA reported from Holland were about 6 weeks after the infection [34] . The exact mechanisms for joint inflammation are not fully understood, however, SARS-CoV-2 infection leads to stimulation of macrophages J o u r n a l P r e -p r o o f which in turn causes release of high levels of cytokines and chemokines which enhance the inflammatory process [40] . Molecular mimicry appears to play a major role in the pathogenesis [7] . Although viral infections are known to potentially induce reactive arthritis [41] , viremia was documented in only 15% of cases of COVID-19 [42] . Interleukin 17 A has been involved in the pathogenesis of both reactive arthritis and spondyloarthritis in general [41] and also in the hyper inflammatory state of COVID-19 [43] .

A plausible explanation for the lower incidence of musculoskeletal inflammation is corticosteroid based COVID-19 treatment which probably dampened the musculoskeletal manifestations. Overall, COVID-19 seems to present mild-to-moderate musculoskeletal symptoms, which are indistinguishable from those associated with other respiratory viruses, such as influenza infection.

SLE is a disease of immune dysregulation leading to multisystem inflammation. Genetic predisposition, environmental triggers, and the hormonal milieu contribute to disease development and activity [44, 45] . COVID-19 infection causes a dysregulated cytokine response with high resultant expression of pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-alpha, which in turn could potentially be exacerbated by the shift in Th1 to Th2 response seen in SLE. It is commonly recognised that SLE, antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) can be triggered by viral illnesses [46--48] .

There are a small number of cases of Systemic Lupus Erythematous (SLE) that have been reported in association with COVID-19 [49] [50] [51] [52] [53] (Table 2 ). All these patients responded well to immunosuppression except the first patient in this series who died. 

There are several reports of the association of COVID-19 with antiphospholipid antibodies (aPL) and thrombosis [54] [55] [56] . It remains to be determined whether aPL are associated with an autoimmune rheumatic disease, or they indicate a viral-induced secondary APS [57] .

These antibodies can also arise transiently in patients with critical illness and infectious diseases through molecular mimicry between bacteria or viruses and beta2-glycoprotein-1, hence the importance of repeat testing at 12 weeks which is part of the APS classification criteria. It is also important to note that increasing age, immunosenescence and the presence of atherosclerosis are factors contributing to the development of aPL [58] . The significance of aPL in COVID-19 patients remains to be clarified. Recent reports of very rare venous sinus thrombosis and venous thromboembolic events related to COVID-19 vaccinations lend support to the concept that these events are due to immune mediated thrombosis linked to the vaccine [59, 60] . These reports clearly need further study, but also open up new possibilities of pathogenesis of thromboembolic phenomena with COVID-19.

Whilst the cases of SLE published at this time fulfil classification criteria, it remains unclear with this small volume of reports as to whether this is a transient phenomenon and what the longer term outcomes are. Lymphopenia is a major immunological abnormality in severe COVID-19, and is strongly associated with increased mortality rates [61, 62] . Lymphopenia is a haematological component in the ACR/EULAR criteria for classification of SLE and was reported in all four case reports although it is not possible to distinguish this from a viral cause.

There are 2 case reports where SLE developed after SARS-CoV-2 infection [63, 64] . These cases fulfil the classification criteria for SLE, and have needed treatment with immunosuppression. The first is an 85 year old woman with positive SARS-CoV-2 J o u r n a l P r e -p r o o f antibodies, but unknown primary infection presenting with digital infarction, thrombocytopenia, pleural effusion, proteinuria and low complement. The second report is of a 35 year old man who had COVID-19 2 months prior to presentation with fever, rash and proteinuria with ANA, dsDNA, Ro and La antibodies. Renal biopsy showed class 1 lupus nephritis. The pathophysiology of severe COVID-19 mimics the B cell responses seen in SLE [65] and there is a possibilityso far unproven, that patients with COVID-19 will be more at risk of developing SLE in the future.

A number of patients with COVID-19 have myalgia, and MDA5 (melanoma differentiation association protein 5) antibodies are also found in a number of patients [40] . There are a number of reports of rhabdomyolysis, presumably secondary to viral myositis [66, 67] . induced viral myositis with creatinine kinase values more than 10 times the upper limit of normal in both cases associated with peak of inflammation. The first case is a 62 year old manual worker who was ventilated for COVID-19 and developed viral myositis but this was then complicated by calcific myositis with significant impairment of shoulder movements.

The second case was similar with prolonged prone ventilation and high muscle enzymes initially complicated later by calcific myositis visible on X-rays [76] .

Renal involvement is well documented in COVID-19; with acute kidney injury, proteinuria, haematuria [77, 78] as well as acute proximal tubular injury and severe endothelial injury at autopsy [79] . Rare cases of glomerulonephritis in patients with COVID-19 have also been described [80] . In addition to direct virus mediated injury, kidney involvement with a COVID-19 infection could be due to systemic hypoxia, hypercoagulability, microangiopathy, rhabdomyolysis, sepsis, cytokine storm, and angiotensin II pathway activation [81] .

In the patient described by Cardoso et al. again there is an overlap between findings consistent with SLE and COVID-19, such as myopericarditis and pulmonary compromise [49] . Pericardial effusion is common in SLE (10-54%) [82] , while it is rare in COVID-19

[83]. Cardiac tamponade is uncommon but reported in both conditions [84] [85] [86] [87] . COVID-19 viral myopericarditis is increasingly being recognised and cardiac MRI is helpful in documenting these changes [88] . A recent study by Zhou et al. showed that autoimmune phenomena exist in some patients with COVID-19. Among 20 subjects with critical COVID-J o u r n a l P r e -p r o o f 19, the authors report a prevalence of between 20% and 50% of autoimmune disease related autoantibodies [89] .

There are limited reports of SLE type illnesses associated with COVID-19 and currently the co-presentation may represent coincidence. Myositis is rare, although myalgia is common and there are limited reports of COVID-19 triggering autoimmune myositis. COVID-19 patients are complex, often with multiorgan involvement; close follow-up becomes imperative if autoimmune phenomena have been triggered. Longer term follow-up data are needed to understand the progression towards a chronic SLE type and chronic myositis type conditions.

A series of publications have reported the development of a vasculitis-like illness in COVID-19 patients, with presentations ranging from vasculitis syndromes [90] to histologic findings of vasculitis seen on postmortem examination [91] . Histologic evidence of COVID-19 induced vasculitis has also been reported in several organs including the lung, liver, kidney, or skin [92, 93] . Manenti et al. describe pathophysiologic observations in small/medium sized arteries in COVID-19; first is an acute endotheliitis, followed by peri-/pan-arteritis with deposition of polyclonal antigen-antibody immune complexes, suggesting a type III hypersensitive acute vasculitis [94, 95] . Many of the predisposing comorbid conditions for COVID-19, including advanced age, diabetes mellitus, hypertension and obesity are also associated with vascular dysfunction and altered endothelial cell metabolism [96] . There is growing recognition that states of heightened innate immune response and a prothrombotic state elicited by innate immune mediators such as that seen in COVID-19 lead to an escalating cascade of inflammatory pathways that promote profound micro and There are case reports documenting the presence of COVID-19 with cutaneous vasculitissevere respiratory failure with ARDS developed in a patient with lower limb vasculitic purpura [103, 104] , a bullous haemorrhagic rash that progressed to necrotic lesions with histopathology confirmed vasculitis of small-and medium-sized cutaneous vessels [105] , purple palpable papules and haemorrhagic blisters characterised histologically as leucocytoclastic vasculitis [106] , and cutaneous vasculitic lesions and gangrene [107] . Camprodon Gómez et al. [108] and Mayor-Ibarguren Inflammation of aorta has been described but attributed to infection with SARS-CoV-2 rather than vasculitis [94] . A reported case of large vessel vasculitis diagnosed on PET CT with associated Covid pneumonia presents the same dilemma [116] . Another case has been reported as LVV but with spontaneous resolution suggesting an infectious aortitis [117] .

There is an inherent difficulty in differentiating "infectious aortitis" from autoimmune vasculitis during an acute infection, the challenges of performing (due to risk of spread of infection) and interpreting PET CT contributes further to this problem. However, LVV could be a complication of COVID-19an Italian study on patients with persistent symptoms after recovery from COVID-19 (so called long COVID) demonstrated 6/10 patients with large vessel vasculitis seen on PET CT imaging [118] . The smooth linear pattern seen in the aorta of these patients could not be differentiated from the similar patterns in patients with large vessel vasculitis. The ascending aorta, arch of aorta, descending aorta and ilio-femorals were the common arteries showing increased uptake in these patients.

Hussein et al. report a case of granulomatosis with polyangiitis with proteinase 3 antibodies that presented with alveolar haemorrhage associated with a four-day history COVID-19

infection. This patient was treated and recovered with pulse intravenous corticosteroids, plasmapheresis and intravenous immunoglobulin [119] . She was not given further Rituximab [122] . Weston et al report a 12 year old girl with likely previous asymptomatic infection with SARS-CoV-2 who developed biopsy proven vasculitis associated with myeloperoxidase antibodies and needing aggressive management through corticosteroids, Rituximab and Cyclophosphamide [123] . A case of bowel perforation secondary to gut vasculitis has been reported [124] and another who eventually died following bowel inflammation and perforation [125] . Another case with medium vessel vasculitis was not given any treatment and resolved spontaneously highlighting the challenges around management of these patients [126] .

Both MPO and PR3 associated vasculitis can lead to pauci-immune GN and there is evidence [128, 129] . Data from United Kingdom registry for vasculitis suggests that AAV patients and patients already on corticosteroids prior to developing COVID-19 have worse outcomes [130] .

Recently, four cases have highlighted SARS-CoV-2 as a trigger for IgA vasculitis, three of which had renal involvement . Anti-SARS-CoV-2 IgA is the first immunoglobulin to be detected in COVID-19 as early as two days after onset [135] . In children with chilblain lesions, IgA antibodies to SARS-CoV-2 spike protein S1 domain are observed, suggesting that their immune response represents mucosal protection that lessens the likelihood of triggering an IgG response [136] . 

Several studies have demonstrated that COVID-19 in children is a relatively mild disease [139] . However, recently a more serious condition characterised by systemic inflammation with clinical or microbiological evidence of exposure to SARS-CoV-2 has been reported [140] . This syndrome is now known as either "Pediatric Inflammatory Multisystem J o u r n a l P r e -p r o o f Syndrome temporally related with COVID-19" (PIMS-TS) [141] , or Multisystem Inflammatory Syndrome in Children (MIS-C) [142, 143] and is currently considered a rare post-COVID-19 complication which, in a minority of cases, can lead to death.

Kawasaki disease (KD) is an acute systemic inflammatory disease of medium-and smallsized vessels that mostly involves children under 5 years old with higher prevalences in Asian countries like Japan [143] . Verdoni et al report a 30-fold increased incidence of Kawasakilike disease after the spread of SARS-CoV-2 to Bergamo, Italy [144] . Researchers from France [145] , United Kingdom [146] , and the USA [141] also described clusters of children with systemic inflammatory disorders without an alternative diagnosis and with clinical or microbiological evidence of exposure to SARS-CoV-2. Interestingly the effect of COVID-19 on patients with KD in Japan seems to be small, Lio et al. revealed only one patient with PIMS-TS with Kawasaki-like presentations [147] ; PIMS-TS apparently shows a predilection for individuals of black or Hispanic descent [146, 148] , suggesting that genetic factors may contribute to its uneven distribution.

The first reported case was in a six-month-old infant who was admitted as a classical Kawasaki and later tested positive for COVID-19; she was treated with aspirin and intravenous immunoglobulin (IVIG) [140] . Children with the symptoms and signs of Kawasaki-like disease diagnosed during the SARS-CoV-2 pandemic and showing evidence of immune response to the virus were older, had a higher rate of cardiac involvement, gastrointestinal symptoms, shock syndrome and features of macrophage activation syndrome (MAS) [144, 146, . Myocarditis is a distinguishing feature of PIMS-TS, at times requiring mechanical circulatory support [145] . Many of these cases occurred after several weeks of quarantine, and it is possible that these subjects suffered from a mild form of J o u r n a l P r e -p r o o f Journal Pre-proof COVID-19 after intrafamilial transmission and severe complications appeared weeks later [151] .

There are a small number of adult-onset Kawasaki Disease Shock Syndrome cases reported; one complicated by coronary aneurysms occurred in a 20-year-old man of East Asian ancestry [152] , a 36-year old Hispanic woman [153] and a 45-year old Hispanic man [154] . Immunomodulatory therapeutic strategies have been shown to be effective for PIMS-TS, including intravenous immunoglobulin (IVIG) and steroids [141, .

KD is an inflammatory vascular disease with an unknown etiology, an association between Kawasaki disease and viral respiratory infections has been suspected . PIMS-TS appears to be a post-acute immunological reaction to an initial SARS-CoV-2 infection, as the majority are asymptomatic during the initial SARS-CoV-2 infection and do not have positive nasopharyngeal swabs but have serological evidence of a previous infection, showing positive IgG against SARS-CoV-2 in most cases [141, . There is also speculation that the SARS-CoV-2 protein could act as a superantigen, similarly to mechanisms widely described for toxic shock syndrome (TSS) .

The information presented in this literature review must be considered along with important limitations, much is yet to be validated using robust statistical methods. The wide diversity of study methodologies, statistical approaches, sample sizes, population characteristics, geographic sites, and quality of publications may have confounded our interpretation of the data. There is also the problem of left censorship bias where patients who died or were lost J o u r n a l P r e -p r o o f Journal Pre-proof to follow-up were not reported. However, in the context of a severe pandemic caused by a novel virus, it is vital to address the emerging data and identify gaps in current knowledge.

Identification of complications of COVID-19 is vital for guiding clinical care, improving patient outcomes, and allocating resources. In this review we primarily aimed to understand the rheumatological manifestations during and after COVID-19 infection. We describe a number of complications including inflammatory arthritis (with some patients developing RA), SLE and myositis amongst the CTD spectrum being commoner and vasculitis.

Vasculitis appears to have a significant role in the initial infection as well as a complication of it. Further studies are necessary to understand the pathogenesis of COVID-19 and its different clinical phenotypes. Follow-ups in the coming months will determine chronicity of these inflammatory conditions. A better understanding of the immune consequences that accompany SARS-CoV-2 infection is required to determine the immunopathogenic mechanisms capable of promoting or contrasting the development of rheumatic manifestations. J o u r n a l P r e -p r o o f Table 2 .

Clinical Characteristics of Coronavirus Disease 2019 in China 2020

Review of the 2019 novel coronavirus

COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons

Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients

COVID-19 cytokine storm: the interplay between inflammation and coagulation

Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine

COVID-19) time musings: Our involvement in COVID-19

pathogenesis, diagnosis, treatment and vaccine planning

RIER investigators group. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Rheumatic Musculoskeletal Diseases and COVID-19, A Review of the First 6 Months of the Pandemic

Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19

Antibody responses to SARS-CoV-2 in patients with COVID-19

Mathematical modelling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis

Covid-19 and autoimmunity

Viral arthritis

Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1. Viruses

Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS

Respiratory viral infections and the risk of rheumatoid arthritis

COVID-19 Can Present With a Rash and be Mistaken for Dengue

Reactive arthritis after COVID-19 infection. RMD Open

The first reactive arthritis case associated with COVID-19

A Case of Reactive Arthritis Secondary to Coronavirus Disease 2019 Infection

Symmetric Peripheral Polyarthritis Developed During SARS-CoV-2 Infection

Reactive Arthritis After COVID-19 Infection

Transient monoarthritis and psoriatic skin lesions following COVID-19

Reactive Arthritis in a 37-Year-Old Female with SARS-CoV2 Infection

Covid-19 related dactyitis

Case of Acute Arthritis Following SARS-CoV-2 Infection

Storgaard MReactive arthritis after COVID-19

Arthritis after SARS-CoV-2 infection

Ann Rheum Dis Epub ahead of print

Onset of rheumatoid arthritis after COVID-19: coincidence or connected

Ten-year-old Boy With Atypical COVID-19 Symptom Presentation: A Case Report

A case of psoriatic arthritis triggered by SARS-CoV-2 infection

Axial presentation of reactive arthritis secondary to Covid-19 infection. Rheumatology (Oxford)

Case Series of Acute Arthritis During COVID-19 Admission

SARS-CoV-2, the autoimmune virus

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Reactive arthritis: treatment challenges and future perspectives

Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review

Systemic lupus erythematosus

Mechanisms of Viral Pathogenisis in Rheumatic Disease

Viral Infections and Antiphospholid Antibodies

Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?

Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology

Systemic Lupus Erythematosus and Varicella-like Rash Following COVID-19 in a Previously Healthy Patient

COVID-19 Presenting as Lupus Erythematosus-Like Syndrome. Disaster Medicine and Public Health Preparedness

A concomitant diagnosis of COVID-19 infection and systemic lupus erythematosus complicated by a macrophage activation syndrome: A new case report

Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. 2020

COVID-19, Antiphospholipid Syndrome and Thrombosis

Lupus Anticoagulant is Frequent in Patients with Covid-19

Entangling COVID-19 Associated Thrombosis into a Secondary Antiphospholipid Antibody Syndrome: Diagnostic and Therapeutic Perspective

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Epub ahead of print

Functional Exhaustion of Antiviral Lymphocytes in COVID-19 Patients

Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China

The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection

Systemic lupus erythematosus manifestation following COVID-19: a case report

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Neuromuscular presentations in patients with COVID-19

Acute viral myositis complicated by rhabdomyolysis: a sole manifestation of COVID-19 infection

Myositis as a manifestation of SARS-CoV-2

Paraspinal myositis in patients with COVID-19 infection

Myopericarditis and myositis in a patient with COVID-19: a case report

Compartment syndrome secondary to viral myositis as initial presentation in COVID-19 patient

New Onset of Unilateral Orbital Myositis following Mild COVID-19 Infection

Case report of COVID-19 in an elderly patient: could SARS-CoV2 trigger myositis?

COVID-19-associated myositis with severe proximal and bulbar weakness. Muscle Nerve

Delayed-onset Necrotizing Myositis following COVID-19

COVID-19 related calcific myositis cases

Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-Cov-2 Infection in Daegu, South Korea: A Brief Descriptive Study

Kidney Disease is Associated with In-hospital Death of Patients with COVID-19

Renal Histopathological Analysis of 26 Post-mortem Findings of Patients with COVID-19 in China

Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection

COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group. Acute Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology

Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus

Cardiac tamponade in systemic lupus erythematosus

The Spectrum of Pericardial Tamponade in Systemic Lupus Erythematosus: Report of Ten Patients

Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19

Systematic review of COVID-19 related myocarditis: Insights on management and outcome

Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19

Kawasaki-like Disease: Emerging Complication During the COVID-19 Pandemic

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome

A Pathological Report of Three COVID-19 Cases by Minimally Invasive Autopsies

Challenging Complications

Type 3 Hypersensitivity in COVID-19 Vasculitis

Downregulation of Survival Signalling Pathways and Increased Apoptosis in the Transition of Pressure Overload-induced Cardiac Hypertrophy to Heart Failure

COVID-19 -A vascular disease

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

COVID toes"): Histologic, immunofluorescence, and immunohistochemical study of 17 cases

Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France

Symetric Cutaneous Vasculitis in COVID-19 Pneumonia

Cutaneous Vasculitis in a Patient With COVID-19

Cutaneous Small Vessel Vasculitis Secondary to COVID-19 Infection: A Case Report

A 47-year-old hispanic man who developed cutaneous vasculitic lesions and gangrene of the toes following admission to hospital with covid-19 pneumonia

Urticarial Vasculitis in COVID-19 Infection: A Vasculopathy-related Symptom?

Leucocytoclastic Vasculitis in a Patient with COVID-19 with Positive SARS-CoV-2 PCR in Skin Biopsy

Large Vessel Stroke as a Presenting Feature of COVID-19 in the Young

Neurological and Neuropsychiatric Complications of COVID-19 in 153 Patients: A UK-wide Surveillance Study

COVID-19 Neurologic Complication with CNS Vasculitis-like Pattern

Vasculitis-related Stroke in Young as a Presenting Feature of Novel Coronavirus Disease (COVID19) -Case Report

Immunosuppression for intracranial vasculitis associated with SARS-CoV-2: therapeutic implications for COVID-19 cerebrovascular pathologyJournal of Neurology

Does SARS-Cov-2 invade the brain? Translational lessons from animal models

SARS-CoV-2 (COVID-19) pneumonia: incidental finding on (18)F-FDG PET/CT study for vasculitis diagnosis

Case of adult large vessel vasculitis after SARS-CoV-2 infection

Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study

Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Vasculitis Presented as Pulmonary Hemorrhage in a Positive COVID-19 Patient: A Case Report

De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19

Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report

New Onset Granulomatosis with Polyangiitis Associated with COVID-19. Case Rep Dermatol Med

Acute ANCA Vasculitis and Asymptomatic COVID-19

Necrotising Vasculitis in Covid-19: watch out for bowel perforation

COVID-19-associated vasculitis and thrombotic complications: from pathological findings to multidisciplinary discussion

Direct endothelial damage and vasculitis due to SARS-CoV-2 in small bowel submucosa of COVID-19 patient with diarrhea

Targeting Potential Drivers of COVID-19: Neutrophil Extracellular Traps

Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia

Mild Course of COVID-19 and Spontaneous Virus Clearance in a Patient With Depleted Peripheral Blood B Cells Due to Rituximab Treatment

Risk factors for severe outcomes in patients with systemic vasculitis & COVID-19: a bi-national registry-based cohort study. Arthritis Rheumatol

COVID-19-Related IgA Vasculitis

Possible association between IgA vasculitis and COVID-19

IgA Vasculitis with Nephritis (Henoch-Schonlein Purpura) in a COVID-19 Patient

Immunoglobulin-A Vasculitis With Renal Involvement in a Patient With COVID-19: A Case Report and Review of Acute Kidney Injury Related to SARS-CoV-2. Can J Kidney Health Dis

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

COVID-19 Associated Vasculitis and Vasculopathy

Intestinal Permeability and IgA Provoke Immune Vasculitis Linked to Cardiovascular Inflammation

New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review

COVID-19 and Kawasaki Disease: Novel Virus and Novel Case

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. (Epub ahead of print) 2020

COVID-19 and multisystem inflammatory syndrome in children and adolescents

EULAR/PReS Endorsed Consensus Criteria for the Classification of Childhood Vasculitides

An Outbreak of Severe Kawasaki-like Disease at the Italian Epicentre of the SARS-CoV-2 Epidemic: An Observational Cohort Study

Acute Heart Failure in Multisystem Inflammatory Syndrome in Children (MIS-C) in the Context of Global SARS-CoV-2 Pandemic

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

Kawasaki Disease or Kawasaki-like Disease: Influence of SARS-CoV-2 Infections in Japan

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Kawasaki-like Multisystem Inflammatory Syndrome in Children During the COVID-19

Prospective Observational Study

Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children

Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic

A Case of Adult-onset Kawasaki Disease Shock Syndrome Complicated by Coronary Aneurysms

Associated Kawasaki-like Multisystem Inflammatory Disease in an Adult

An Adult With Kawasaki-like Multisystem Inflammatory Syndrome Associated with COVID-19

Seasonality of Kawasaki Disease: A Global Perspective

Concurrent Respiratory Viruses and Kawasaki Disease

Evaluation of the temporal association between Kawasaki disease and viral infections in South Korea

An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations

An Immunogenetic and Molecular Basis for Differences in Outcomes of Invasive Group A Streptococcal Infections

Antibody-dependent Enhancement of Virus Infection and Disease